The article presents industry contributors’ views on the continuing role of small molecules alongside newer drug modalities.
Approach:
Perspectives: The article presents comments from five contributors in biotechnology, drug discovery, and computational science.
Topics: Contributors discuss oral administration, tissue penetration, intracellular targets, advances in medicinal chemistry and computational methods, protein degraders and macrocycles, manufacturing, and health-system fit.
Key Findings:
Contributors describe small molecules as continuing to have roles alongside cell therapies, biologics, and RNA-based approaches, with modality choice depending on biological and patient needs.
Contributors cite oral administration as a potential convenience advantage, particularly for people receiving long-term treatment.
Contributors describe small molecules as useful for intracellular targets and cite tissue penetration, including access to the central nervous system, as an advantage.
Contributors discuss advances in medicinal chemistry, computational methods, protein degradation, and work beyond traditional rule-of-five limits as expanding small-molecule research.
Contributors cite relatively straightforward or scalable manufacturing and the fit of oral medicines with established health-care and reimbursement systems.
Interpretation:
The contributors present small molecules as one modality among several, with their suitability depending on the target and patient needs.
Limitations:
The supplied context consists of attributed perspectives from industry contributors; it does not provide independent comparative clinical evidence.
Claims about convenience, access, manufacturing, and modality advantages are presented by contributors and are not independently evaluated in the supplied context.
Conclusion:
The contributors describe small molecules as continuing to have a role and discuss advances they believe are expanding the scope of small-molecule research.
Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.
